MACROGENICS, INC. (MGNX) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $637.00K; Additional Paid in Capital, Common StockUSD $1.30B; AOCI, Debt Securities, Available-for-sale, Adjustment, after TaxUSD $-15.00K; Retained Earnings (Accumulated Deficit)USD $-1.26B.
- 2026-03-31: Common Stock, Value, IssuedUSD $636.00K; Additional Paid in Capital, Common StockUSD $1.30B; AOCI, Debt Securities, Available-for-sale, Adjustment, after TaxUSD $-27.00K; Retained Earnings (Accumulated Deficit)USD $-1.28B.
- 2025-12-31: Common Stock, Value, IssuedUSD $633.00K; Additional Paid in Capital, Common StockUSD $1.30B; AOCI, Debt Securities, Available-for-sale, Adjustment, after TaxUSD $32.00K; Retained Earnings (Accumulated Deficit)USD $-1.24B.
- 2025-09-30: Common Stock, Value, IssuedUSD $633.00K; Additional Paid in Capital, Common StockUSD $1.30B; AOCI, Debt Securities, Available-for-sale, Adjustment, after TaxUSD $5.00K; Retained Earnings (Accumulated Deficit)USD $-1.23B.
MACROGENICS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Additional Paid in Capital USD | Treasury Stock, Value USD | Treasury Stock, Retired, Par Value Method, Amount USD | Treasury Stock, Retired, Cost Method, Amount USD | Treasury Stock, Number of Shares Held (Deprecated 2016-01-31) shares |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $637.00K | $1.30B | $-15.00K | $-1.26B | $42.87M | $42.87M | 3 month · $1.97M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $636.00K | $1.30B | $-27.00K | $-1.28B | $21.20M | $21.20M | 3 month · $2.65M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $633.00K | $1.30B | $32.00K | $-1.24B | $55.59M | $55.59M | 12 month · $14.29M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $633.00K | $1.30B | $5.00K | $-1.23B | $67.00M | $67.00M | 3 month · $3.55M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $632.00K | $1.29B | $-7.00K | $-1.25B | $46.62M | $46.62M | 3 month · $3.68M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $631.00K | $1.29B | $-1.00K | $-1.21B | $79.12M | $79.12M | 3 month · $4.39M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $628.00K | $1.29B | $4.00K | $-1.17B | $116.06M | $116.06M | 12 month · $29.44M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $627.00K | $1.27B | $14.00K | $-1.15B | $120.07M | $120.07M | 3 month · $5.97M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $627.00K | $1.27B | $-24.00K | $-1.21B | $57.82M | $57.82M | 3 month · $6.69M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $626.00K | $1.26B | $-35.00K | $-1.15B | $106.15M | $106.15M | 3 month · $5.51M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $621.00K | $1.25B | $-6.00K | $-1.10B | $152.61M | $152.61M | 12 month · $18.37M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $620.00K | $1.25B | $-34.00K | $-1.06B | $193.98M | $193.98M | 3 month · $4.75M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $619.00K | $1.25B | $-72.00K | $-1.07B | $171.54M | $171.54M | 3 month · $4.44M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $618.00K | $1.24B | $8.00K | $-1.13B | $109.27M | $109.27M | 3 month · $4.79M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $617.00K | $1.24B | $-5.00K | $-1.09B | $142.01M | $142.01M | 12 month · $20.44M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $615.00K | $1.23B | $-113.00K | $-1.11B | $122.96M | $122.96M | 3 month · $5.08M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $615.00K | $1.22B | $-326.00K | $-1.08B | $142.48M | $142.48M | 3 month · $5.35M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $613.00K | $1.22B | $-283.00K | $-1.04B | $178.21M | $178.21M | 3 month · $5.22M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $613.00K | $1.21B | $-61.00K | $-973.94M | $239.62M | $239.62M | 12 month · $23.13M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $613.00K | $1.21B | $-3.00K | $-915.91M | $291.44M | $291.44M | 3 month · $6.31M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $601.00K | $1.18B | $1.00K | $-863.03M | $319.05M | $319.05M | 3 month · $6.11M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $600.00K | $1.17B | $11.00K | $-823.09M | $350.53M | $350.53M | 3 month · $5.24M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $562.00K | $1.07B | $-7.00K | $-771.82M | $295.88M | $295.88M | 12 month · $20.68M | (m) | (m) | 12 month · $0.00 | (m) | (m) |
| 2020-09-30 | $562.00K | $1.06B | $2.00K | $-769.73M | $291.58M | $291.58M | 3 month · $5.80M | (m) | (m) | (m) | 3 month · $0.00 | (m) |
| 2020-06-30 | $534.00K | $980.92M | $17.00K | $-733.69M | $247.78M | $247.78M | 3 month · $5.14M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $492.00K | $876.82M | $72.00K | $-686.81M | $190.57M | $190.57M | 3 month · $4.45M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $490.00K | $872.20M | $16.00K | $-642.08M | $230.63M | $230.63M | 12 month · $19.57M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $489.00K | $866.37M | $23.00K | $-611.69M | $255.20M | $255.20M | 3 month · $5.35M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $489.00K | $860.98M | $34.00K | $-567.05M | $294.45M | $294.45M | 3 month · $4.93M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $488.00K | $855.42M | $0.00 | $-535.29M | $320.62M | $320.62M | 3 month · $3.75M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $424.00K | $732.73M | $-3.00K | $-490.27M | $242.88M | $242.88M | 12 month · $16.52M | (m) | (m) | 12 month · $0.00 | (m) | (m) |
| 2018-09-30 | $422.00K | $727.85M | $0.00 | $-445.63M | $282.64M | $282.64M | 3 month · $4.52M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $422.00K | $723.20M | $17.00K | $-411.60M | $312.04M | $312.04M | 3 month · $4.21M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $370.00K | $615.28M | $-23.00K | $-368.36M | $247.28M | $247.28M | 3 month · $3.39M | (m) | (m) | (m) | (m) | (m) |
| 2018-01-01 | (m) | (m) | (m) | $-318.82M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $369.00K | $611.27M | $-61.00K | $-312.34M | $299.24M | $299.24M | 12 month · $14.74M | (m) | (m) | 12 month · $0.00 | (m) | (m) |
| 2017-09-30 | $368.00K | $607.19M | $-27.00K | $-418.07M | $189.47M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $367.00K | $602.09M | $-80.00K | $-371.02M | $231.35M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $350.00K | $564.77M | $-108.00K | $-330.37M | $234.64M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $349.00K | $561.20M | $-82.00K | $-292.71M | $268.75M | (m) | 12 month · $12.16M | (m) | (m) | 12 month · $0.00 | (m) | (m) |
| 2016-09-30 | $348.00K | $557.67M | $18.00K | $-257.93M | $300.10M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $347.00K | $553.65M | $59.00K | $-224.09M | $329.98M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $345.00K | $550.41M | $52.00K | $-264.55M | $286.25M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $343.00K | $547.18M | $-5.00K | $-234.19M | $313.34M | (m) | 12 month · $7.85M | (m) | $0.00 | 12 month · $0.00 | (m) | 0.00 |
| 2015-09-30 | $342.00K | $544.72M | (m) | $-205.74M | $339.33M | (m) | (m) | (m) | $0.00 | (m) | (m) | 0.00 |
| 2015-06-30 | $301.00K | $401.68M | (m) | $-190.29M | $211.69M | (m) | (m) | (m) | $0.00 | (m) | (m) | 0.00 |
| 2015-03-31 | $300.00K | (m) | (m) | $-168.92M | $230.99M | (m) | (m) | $399.63M | $19.00K | (m) | (m) | 865.00 |
| 2014-12-31 | $280.00K | $335.07M | $0.00 | $-214.05M | $121.29M | (m) | 12 month · $3.24M | $335.07M | $19.00K | 12 month · $0.00 | (m) | 865.00 |
| 2014-09-30 | $278.00K | (m) | (m) | $-195.03M | $139.09M | (m) | (m) | $333.84M | (m) | (m) | (m) | 0.00 |
| 2014-06-30 | $277.00K | (m) | (m) | $-191.10M | $141.98M | (m) | (m) | $332.80M | $0.00 | (m) | (m) | 0.00 |
| 2014-03-31 | $274.99K | (m) | (m) | $-178.84M | $153.22M | (m) | (m) | $331.79M | (m) | (m) | (m) | 0.00 |
| 2013-12-31 | $252.00K | (m) | (m) | $-175.73M | $78.91M | (m) | 12 month · $862.00K | $254.45M | $58.00K | (m) | (m) | 14.38K |
| 2013-09-30 | $21.25K | (m) | (m) | $-172.53M | $-4.05M | (m) | (m) | $165.57M | $57.74K | (m) | (m) | 14.38K |
| 2012-12-31 | $10.99K | (m) | (m) | $-175.47M | $-8.24M | (m) | 12 month · $838.00K | $164.33M | $57.74K | (m) | (m) | 14.38K |
| 2011-12-31 | (m) | (m) | (m) | (m) | $-17.48M | (m) | 12 month · $2.35M | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) | $-38.63M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |